RedHill Biopharma Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RDHL research report →
About the company
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea.
- CEO
- Dror Ben-Asher
- IPO
- 2013
- Employees
- 35
- HQ
- Tel Aviv, IL
Price Chart
- Market Cap
- $2.55M
- P/E
- -0.41
- P/S
- 0.63
- P/B
- 0.34
- EV/EBITDA
- 0.08
- Div Yield
- 0.00%
- Gross Margin
- 60.60%
- Op Margin
- -107.33%
- Net Margin
- -101.32%
- ROE
- 5740.28%
- ROIC
- -69.56%
- Revenue
- $286.00K · -96.44%
- Net Income
- $-429,000 · 94.81%
- EPS
- $0.00 · 100.00%
- Op Income
- $-7,909,000
- FCF YoY
- -2.96%
- 52W High
- $3.31
- 52W Low
- $0.71
- 50D MA
- $0.95
- 200D MA
- $1.14
- Beta
- 4.97
- Avg Volume
- 210.01K
Get TickerSpark's AI analysis on RDHL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 6, 26 | Raday Gilead | sell | 15,740,000 |
| Apr 6, 26 | Raday Gilead | other | 30,780,000 |
| Mar 18, 26 | Tsimchi Ofer | other | 0 |
| Mar 18, 26 | Tsimchi Ofer | other | 36,440,000 |
| Mar 18, 26 | Tsimchi Ofer | other | 180,000 |
| Mar 18, 26 | Scruggs Rick D | other | 0 |
| Mar 18, 26 | Scruggs Rick D | other | 73,640,000 |
| Mar 18, 26 | Scruggs Rick D | other | 840,000 |
| Mar 18, 26 | Reed Kenneth | other | 0 |
| Mar 18, 26 | Reed Kenneth | other | 25,830,000 |
Our RDHL coverage
Recent articles, reports, and earnings notes.
No research on RDHL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RDHL report →Similar companies
Peers in the same neighborhood.